M&G plc’s AstraZeneca AZN Stock Holding History

M&G plc’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$838M	Buy	4,482,712 +278,513	+7%	+$52.4M	4.17%	3
2026 Q1	$817M	Buy	+4,204,199	New	+$811M	4.22%	3

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

M&G plc's AZN Position: Q2 2026 in Review

M&G plc increased its AstraZeneca (AZN) stake by 6.6% in Q2 2026, buying an estimated $52.4M and bringing the position to 4,482,712 shares worth $838M. The position accounts for 4.17% of the portfolio, ranked #3.

M&G plc first reported a position in AZN in Q1 2026 and has held it in 2 quarters since. 1,498 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

M&G plc held 4,482,712 shares of AstraZeneca worth $838M as of Q2 2026.
M&G plc bought 278,513 AstraZeneca shares in Q2 2026, an estimated $52.4M.
AstraZeneca made up 4.17% of M&G plc's portfolio in Q2 2026, its #3 holding.
M&G plc first reported a position in AstraZeneca in Q1 2026 and has held it in 2 quarters since.
1,498 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on M&G plc's 13F filing for Q2 2026, filed 6 Aug 2026.